Graves 甲状腺功能亢进症治疗选择的比较效果:历史性队列研究
该历史性队列纳入2002年1月至2008年12月在妙佑医疗国际(Mayo Clinic)罗切斯特院区诊断并完成随访的720例Graves病成人患者,平均年龄49.3岁,平均随访3.3年。初始治疗为放射性碘(RAI)者占75.4%、抗甲状腺药物(ATDs)占16.4%、甲状腺切除术占2.6%、观察占5.6%。ATDs总体失败率为48.3%,RAI为8%(HR=7.6;P<0.0001);手术成功率100%;观察者80%最终需要治疗。
要点
- RAI是最常用治疗方式,在本队列中显示出最佳疗效与安全性。
- ATDs失败率48.3%(RAI为8%,HR=7.6;P<0.0001),43例(17.3%)出现不良反应。
- 手术成功率100%,在经验丰富的外科医生手中非常有效且相对安全。
核心结论
- RAI是本队列中最常用的治疗方式,并显示出最佳疗效与安全性。
- 手术在经验丰富的外科医生手中也非常有效且相对安全。
- ATDs虽可保留甲状腺功能,但复发率高且不良反应明显。
研究设计与样本
- 历史性队列研究,纳入2002年1月至2008年12月在妙佑医疗国际(Mayo Clinic)罗切斯特院区诊断并完成随访的连续成人Graves病患者,共720例。
- 从电子病历中手工和电子提取治疗方式、疾病复发及不良反应数据,采用Kaplan-Meier分析评估治疗与无复发生存的关系。
主要发现
- 患者平均年龄49.3岁,平均随访3.3年;女性占76.7%,吸烟者占17.1%。
- 初始治疗为RAI者占75.4%、ATDs占16.4%、甲状腺切除术占2.6%,5.6%选择观察。
- 随访期间ATDs总体失败率为48.3%,RAI为8%(HR=7.6;P<0.0001)。
- 手术成功率为100%;观察患者中80%最终需要治疗。
- ATDs治疗者中43例(17.3%)出现不良反应,最常见为味觉障碍(4.4%)、皮疹(2.8%)、恶心/胃部不适(2.4%)、瘙痒(1.6%)和荨麻疹(1.2%)。
临床怎么用
- 这些数据可为医生与患者讨论Graves病治疗选择提供信息。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimum therapy for Graves' disease (GD) is chosen following discussion between physician and patient regarding benefits, drawbacks, potential side effects, and logistics of the various treatment options, and it takes into account patient values and preferences. This cohort study aimed to provide useful information for this discussion regarding the usage, efficacy, and adverse-effect profile of radioactive iodine (RAI), antithyroid drugs (ATDs), and thyroidectomy in a tertiary healthcare facility. METHODS: The cohort included consecutive adults diagnosed with GD from January 2002 to December 2008, who had complete follow-up after treatment at the Mayo Clinic, Rochester, Minnesota. Data on treatment modalities, disease relapses, and adverse effects were extracted manually and electronically from the electronic medical records. Kaplan-Meier analyses were performed to evaluate the association of treatments with relapse-free survival. RESULTS: The cohort included 720 patients with a mean age of 49.3 years followed for a mean of 3.3 years. Of these, 76.7% were women and 17.1% were smokers. The initial therapy was RAI in 75.4%, ATDs in 16.4%, and thyroidectomy in 2.6%, while 5.6% opted for observation. For the duration of follow-up, ATDs had an overall failure rate of 48.3% compared with 8% for RAI (hazard ratio = 7.6; p < 0.0001). Surgery had a 100% success rate; 80% of observed patients ultimately required therapy. Adverse effects developed in 43 (17.3%) patients treated with ATDs, most commonly dysgeusia (4.4%), rash (2.8%), nausea/gastric distress (2.4%), pruritus (1.6%), and urticaria (1.2%). Eight patients treated with RAI experienced radiation thyroiditis (1.2%). Thyroidectomy resulted in one (2.9%) hematoma and one (2.85%) superior laryngeal nerve damage, with no permanent hypocalcemia. CONCLUSIONS: RAI was the most commonly used modality within the cohort and demonstrated the best efficacy and safety profile. Surgery was also very effective and relatively safe in the hands of experienced surgeons. While ATDs allow preservation of thyroid function, a high relapse rate combined with a significant adverse-effect profile was documented. These data can inform discussion between physician and patient regarding choice of therapy for GD.
引用
- Sundaresh V, Brito JP, Thapa P, et al. Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study. Thyroid. 2017. PMID: 28049375. doi:10.1089/thy.2016.0343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。